| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Strategic partnership will link DNA data with rich clinical data to identify novel biomarkers for targeted cancer therapiesThe ...
Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target f...
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that new data from across its oncology...
Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price tar...
This marks the second FDA-approved indication for Guardant360 CDx as a companion diagnostic in breast cancer treatmentESR1 muta...
TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $63 to $72.
Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $60 to $70.